About Sermorelin Medicinal

What this site is

Sermorelin Medicinal is an independent editorial project that publishes summaries of the peer-reviewed research literature on sermorelin — the GHRH(1-29) peptide. We read the published record and stencil it onto the wall: the mechanism, the studied doses, the body-composition findings, the half-life, and the hard limits of the adult data, each figure carried back to the study that measured it.

We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

What the name means

The word "medicinal" in this domain is editorial framing, not a service claim. It marks the position this publisher occupies relative to the literature — reading sermorelin as a subject of medical research — not a statement that the site offers treatment, consultation, compounding, or prescriptions. There is no clinic behind this wall, no dispensary, and no counter.

We do not have doctors, pharmacists, or a clinical team. When a page reports what was administered in a study, it reports a study parameter — never an instruction. The site gives no human dosing recommendations anywhere.

How we read the record

Three rules govern the reading. First, numbers first, attribution after: every quantitative claim — a height velocity, an IGF-1 percentage, a half-life, a body-fat change — maps to a numbered citation with a DOI or PubMed link. Second, lanes stay separate: where body-composition evidence comes from the stabilized analog tesamorelin rather than from sermorelin itself, we say so, so a drug-class finding is never dressed up as a sermorelin-specific result.

Third, the limits are stencilled as loudly as the findings. The anti-aging marketing for this compound outpaces its evidence; the approval history is widely misstated; the long-term adult safety data are thin. We mark each of those in plain view rather than burying them.

On the regulatory record

We state sermorelin's regulatory history precisely because it is so often garbled. Sermorelin was a fully FDA-approved prescription product for pediatric growth-hormone deficiency, withdrawn from the US market in 2008 for commercial reasons — not safety or efficacy — and is now prepared by compounding pharmacies as a Category 1 bulk drug substance under FDA's Section 503A framework. It is a formerly approved, now-compounded GHRH analog: not currently a marketed finished drug, and not a compound that was "never approved." Growth-hormone secretagogues, including GHRH analogs, are also prohibited in sport under the WADA Prohibited List.